Drug Trial Radar · NCT00994149
Diazoxide In the Management Of Hypoglycemic Neonates
Last checked: Nov 20, 2026Latest source record: Oct 14, 2009 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
100
Planned (sponsor's estimate)
Start
Oct 2009
Primary completion
Oct 2011
Study completion Oct 2011
Sponsor
- Lead sponsor
- University of SaskatchewanAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 14, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, up to 12 hours
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Diazoxide is an oral hyperglycemic medication. Diazoxide has been proven effective for treating hypoglycemia in infants and children with some types of persistent hyperinsulinemic hypoglycemia. The mechanism of action results in decreased insulin secretion. One of the causes of hypoglycemia in infants of diabetic mothers occurs due to a transient hyperinsulinemic state postnatally. The investigators have clinical experience and success using diazoxide in their unit for patients with hypoglycemia not adequately managed with intravenous (iv) dextrose and enteral supplementation. In this randomized controlled study the investigators expect that by using diazoxide as the initial treatment for infants of diabetic mothers with asymptomatic hypoglycemia (blood glucose of 2.5 to 2.0mmol/L), the investigators will be able to decrease the number of infants requiring an intravenous by at least thirty percent.
Conditions
- Infant, Newborn, Diseases
- Pregnancy in Diabetics
- Infant, Diabetic Mother
- Hypoglycemia
- Infant, Large for Gestational Age
Interventions
DiazoxideDrug
10mg/kg/d divide every 8 hours
Ora-plusDrug
placebo, give every 8 hours.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Blood glucose measurement less than 2.0mmol/LTime frame: 14 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Royal University Hospital
Saskatoon, Saskatchewan, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.